Optimizing the safety of biologic therapy for IBD

[1]  F. Sung,et al.  A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia. , 2012, The oncologist.

[2]  G. Porro,et al.  Biologic Therapy for Inflammatory Bowel Disease , 2012, Drugs.

[3]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[4]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[5]  F. Carrat,et al.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.

[6]  C. Lees,et al.  Lack of association between cervical dysplasia and IBD: A large case–control study , 2009, Inflammatory bowel diseases.

[7]  W. Sandborn,et al.  Adalimumab safety in global clinical trials of patients with Crohn's disease , 2009, Inflammatory bowel diseases.

[8]  G. Melmed.  Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. , 2009, Inflammatory bowel diseases.

[9]  B. Sands,et al.  Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  E. Kliewer,et al.  Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. , 2009, Gastroenterology.

[11]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[12]  P. Munkholm,et al.  Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  R. Caprilli,et al.  Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  M. Turner,et al.  Safety of Infliximab and Other Crohnʼs Disease Therapies: Treat™ Registry Data with 24,575 Patient-Years of Follow-up , 2008 .

[15]  Madhukar Pai,et al.  Systematic Review: T-Cellbased Assays for the Diagnosis of Latent Tuberculosis Infection: An Update , 2008, Annals of Internal Medicine.

[16]  S. Kane.  Abnormal Pap smears in inflammatory bowel disease. , 2008, Inflammatory bowel diseases.

[17]  R. Panaccione,et al.  Hepatosplenic T cell lymphoma in inflammatory bowel disease , 2008, Gut.

[18]  L. Peyrin-Biroulet,et al.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  A. Zinsmeister,et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.

[20]  S. Kane,et al.  Higher Incidence of Abnormal Pap Smears in Women With Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.

[21]  F. Schmidt.  Meta-Analysis , 2008 .

[22]  Y. Yazdanpanah,et al.  Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis , 2007, Gut.

[23]  P. Rutgeerts,et al.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2007, Gut.

[24]  C. Berkelhammer,et al.  Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. , 2007, Inflammatory bowel diseases.

[25]  A. Griffiths,et al.  Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? , 2007, Inflammatory bowel diseases.

[26]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[27]  M. Daperno,et al.  Infliximab and the risk of latent viruses reactivation in active Crohn's disease , 2007, Inflammatory bowel diseases.

[28]  Louis J. Cohen,et al.  Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  G. D'Haens.  Risks and benefits of biologic therapy for inflammatory bowel diseases , 2007, Gut.

[30]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[31]  L. Biancone,et al.  Treatment with biologic therapies and the risk of cancer in patients with IBD , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[32]  D. Baker.  Natalizumab: overview of its pharmacology and safety. , 2007, Reviews in gastroenterological disorders.

[33]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[34]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[35]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[37]  S. Targan,et al.  Patients with Inflammatory Bowel Disease are at Risk for Vaccine-Preventable Illnesses , 2005, The American Journal of Gastroenterology.

[38]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[39]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[40]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[41]  F. Rizzello,et al.  Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study , 2005, Gut.

[42]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[43]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[44]  M. Björkholm,et al.  Risk of haematopoietic cancer in patients with inflammatory bowel disease , 2005, Gut.

[45]  B. Sands,et al.  Guidelines for immunizations in patients with inflammatory bowel disease. , 2004, Inflammatory bowel diseases.

[46]  F. González‐Huix,et al.  Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis , 2004, Gut.

[47]  P. Hellström,et al.  Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County , 2004, Gut.

[48]  P. Rutgeerts,et al.  Optimizing anti-TNF treatment in inflammatory bowel disease. , 2004, Gastroenterology.

[49]  W. Mow,et al.  High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[51]  A. Zinsmeister,et al.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.

[52]  K. Van Steen,et al.  Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. , 2003, Gastroenterology.

[53]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[54]  S. Ghosh.  Alpha 4 integrin blockade in inflammatory bowel disease. , 2003, Annals of the rheumatic diseases.

[55]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[56]  C. Brensinger,et al.  Inflammatory bowel disease is not associated with an increased risk of lymphoma. , 2001, Gastroenterology.

[57]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[58]  E. Kliewer,et al.  Cancer risk in patients with inflammatory bowel disease , 2001, Cancer.

[59]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[60]  A. Rowlinson.  Inflammatory bowel disease. 1: Aetiology and pathogenesis. , 1999, British journal of nursing.

[61]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[62]  C. Fiocchi.  Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[63]  R. Breiman,et al.  Prevention of pneumococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1997 .

[64]  P. Munkholm,et al.  Intestinal cancer risk and mortality in patients with Crohn's disease. , 1993, Gastroenterology.

[65]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[66]  Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1992, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[67]  D. David,et al.  Aetiology and Pathogenesis , 1982 .